Autopsy report · NCT00111917

Beryllium Infliximab Study: Clinical Interventional Trial

“Not enough patients meeting criteria to enroll in the time period”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 3 years 11 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 5 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Maier, Lisa, M.D.

Sponsor type

University, hospital or other

Conditions

Berylliosis; Beryllium Disease

Interventions

Infliximab; Placebo

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use
  “Insufficient patient enrollment.” (73% match in meaning)
• Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal
  “Lack of Patient Enrollment” (72% match in meaning)
• Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
  “Unable to enroll appropriate patients” (71% match in meaning)
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (70% match in meaning)
• Digital Therapeutic vs Educational App for Depression Among Adolescents
  “Terminated due to difficulty enrolling patients in the proposed time frame” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.